Melanoma Patients under Vemurafenib: Prospective Follow-Up of Melanocytic Lesions by Digital Dermoscopy  Marie Perier-Muzet, Luc Thomas, Nicolas Poulalhon, Sébastien Debarbieux, Pierre-Paul Bringuier, Gerard Duru, Lauriane Depaepe, Brigitte Balme, Stephane Dalle  Journal of Investigative Dermatology  Volume 134, Issue 5, Pages 1351-1358 (May 2014) DOI: 10.1038/jid.2013.462 Copyright © 2014 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 1 Percentage of dermoscopic changes observed during follow-up. Journal of Investigative Dermatology 2014 134, 1351-1358DOI: (10.1038/jid.2013.462) Copyright © 2014 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 2 Dermoscopic features during follow-up of three melanocytic lesions in three patients: patient 12 (first line), patient 21 (second line), and patient 32 (third line). Journal of Investigative Dermatology 2014 134, 1351-1358DOI: (10.1038/jid.2013.462) Copyright © 2014 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 3 Evolution under vemurafenib of the 10 analyzed dermoscopic criteria (in percent) over the time. Journal of Investigative Dermatology 2014 134, 1351-1358DOI: (10.1038/jid.2013.462) Copyright © 2014 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 4 Distribution of patients depending on their percentage of changed pigmented lesions. Journal of Investigative Dermatology 2014 134, 1351-1358DOI: (10.1038/jid.2013.462) Copyright © 2014 The Society for Investigative Dermatology, Inc Terms and Conditions